Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Dec 11;5(12):e008338.
doi: 10.1136/bmjopen-2015-008338.

Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial

Hye-Yoon Lee  1 , Jong-Kil Nam  2 , Sang-Don Lee  2 , Dong-Hoon Lee  2 , Ji-Yeon Han  2 , Young-Ju Yun  3 , Ji-Hye Lee  4 , Hye-Lim Park  1 , Seong-Ha Park  3 , Jung-Nam Kwon  3
Affiliations
Randomized Controlled Trial

Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial

Hye-Yoon Lee et al. BMJ Open. .

Abstract

Introduction: This study aims to explore the feasibility of using moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with conventional treatment for patients with benign prostatic hyperplasia accompanying moderate to severe lower urinary tract symptoms.

Methods and analysis: A total of 60 patients diagnosed with benign prostatic hyperplasia by a urologist based on prostate size, prostate-specific antigen and clinical symptoms will participate of their own free will; urologists will monitor the patients and evaluate their symptoms. The patients will be randomised to either a conventional group or an integrative group with a 1:1 allocation according to computer-generated random numbers concealed in opaque, sealed, sequentially numbered envelopes. Watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs will be offered as conventional treatment. Integrative treatment will include moxibustion therapy in addition to the conventional treatment. The moxibustion therapy will be conducted twice a week for 4 weeks on the bilateral acupoints SP6, LR3 and CV4 by a qualified Korean medical doctor. The primary outcome will be the International Prostate Symptom Score (IPSS) after eight sessions. The secondary outcomes will be the post-void residual urine volume, the maximum urinary flow rate, IPSS, the results of a Short-Form 36-Question Health Survey after 12 weeks, and the patients' global impression of changes at each visit.

Ethics and dissemination: Written informed consent will be obtained from all participants. This study was approved by the institutional review boards of both Pusan National University Yangsan Hospital and Pusan National University Korean Medicine Hospital. The trial results will be disseminated through open-access journals and conferences.

Trial registration number: NCT02051036.

Keywords: integrative medicine; lower urinary tract symptoms; moxibustion.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial flowchart. BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; KMD, Korean medical doctor; PSA, prostate-specific antigen; TRUS, transrectal ultrasonography.
Figure 2
Figure 2
Timeframe of the integrative treatment group (I.G) and conventional treatment group (C.G).
Figure 3
Figure 3
Apparatus-type moxibustion on acupoint CV4.
Figure 4
Figure 4
Mini-pillar-type moxibustion on bilateral acupoints SP6 and LR3.
See this image and copyright information in PMC

Comment in

References

    1. Statistics Korea. Prevalence of Self-Recognition on Chronic Disease and Doctor's Diagnosis Rate by General Feature of The Aged (Over 65 Years Old) 2011. http://kosis.kr/statHtml/statHtml.do?orgId=117&tblId=DT_11771_2011N036&c...
    1. Statistics Korea. Outpatient Benefits by Frequency of Disease (Male). 2013. http://kosis.kr/statHtml/statHtml.do?orgId=350&tblId=DT_35001_A080011&co...
    1. McVary KT, Roehrborn CG, Avins AL et al. . Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793–803. 10.1016/j.juro.2011.01.074 - DOI - PubMed
    1. Oelke M, Bachmann A, Descazeaud A et al. . EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40. 10.1016/j.eururo.2013.03.004 - DOI - PubMed
    1. Shim SR, Kim JH, Choi H et al. . General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis. Curr Med Res Opin 2015;31:353–65. 10.1185/03007995.2014.980887 - DOI - PubMed

Publication types

MeSH terms

Associated data